Infosys Ltd Falls 2.86% to ₹1,112.50 as IT Sector Bleeds; 4baseCare Closes Series B at ₹128 Crore With Infosys Backing

Not every decline needs a single trigger. Infosys Ltd (NSE: INFY) dropped 2.86% to ₹1,112.50 on June 11, 2026, with the broader IT sector dragging peers down simultaneously. TCS fell 1.62%, HCL Technologies dropped 3.04%, and Wipro slipped 0.88% in the same session. The selloff is sector-driven, not earnings-driven. Infosys Ltd delivered $20,158 million in FY26 revenues, crossing the $20 billion mark for the first time, with 3.1% constant currency growth, large deal wins of $14.9 billion, and free cash flow of $3.73 billion. Fundamentals remain intact. The market is repricing the near-term macro uncertainty.

FY26 in the Books — The Numbers Infosys Delivered

Infosys Ltd reported Q4 FY26 revenue of $5,040 million, up 4.1% year-on-year in constant currency, with an operating margin of 20.9%. Basic EPS grew 23.8% year-on-year to ₹21.01 for the quarter. The full year told a similarly solid story.

FY26 Full-Year Performance at a Glance

• Full-year IFRS operating margin: 20.3%; adjusted operating margin: 21.0%
• Large deal TCV: $14.9 billion with 55% net new, a measure of fresh business, not renewals
• Free cash flow adjusted for Labour Code and income tax refunds: $3.5 billion for the full year; FCF conversion at 106% of net profit
• FY27 revenue growth guidance: 1.5%–3.5% in constant currency; operating margin guidance: 20%–22%
• Next quarterly earnings report: July 23, 2026

The 4baseCare Connection — Infosys-Backed Startup Closes at ₹128 Crore

Here is where the two stories intersect. Precision oncology startup 4baseCare closed its Series B funding round at ₹128 crore on June 11, 2026, after raising a final tranche of ₹38 crore six months after a first close of ₹90 crore co-led by investors Ashish Kacholia and Lashit Sanghvi.

Infosys participated in 4baseCare’s earlier ₹50 crore Series A round in 2024, making it a strategic backer of the Bengaluru-based AI-driven cancer diagnostics platform. The completed Series B validates that early call.

What 4baseCare Does With the ₹128 Crore

• Capital will be deployed into expanding its genomics laboratory network across India, the Middle East, Southeast Asia, Latin America, and Central Asia.
• Funds also scale OncoTwin, 4baseCare’s AI-based precision oncology platform that supports clinicians with real-world, clinically actionable cancer treatment insights.
• 4baseCare was founded in 2018 by Hitesh Goswami and Kshitij Rishi, building population-specific clinico-genomic datasets that combine genetic, clinical, environmental, and lifestyle data.
• OncoTwin was selected for the MSK iHub program at Memorial Sloan Kettering Cancer Center in New York, giving the platform global clinical validation.

Dividend and Calendar — What’s Next for Infosys Ltd

Infosys Ltd announced a cash dividend of $0.259 per share with an ex-date of June 10, 2026. The company employs 328,590 people globally as of June 11, 2026, and has an EBITDA of ₹417.78 billion with an EBITDA margin of 24.02%. Peer names Wipro (NSE: WIPRO), HCL Technologies (NSE: HCLTECH), and Tech Mahindra (NSE: TECHM) are all navigating the same IT sector headwinds today.

Final Thoughts

Infosys Ltd’s June 11 decline is not a fundamental reset; it is a sector recalibration in a risk-off session. Crossing $20 billion in revenue, maintaining 55% net-new deal wins, and guiding FY27 margin at 20–22% all signal structural stability. The 4baseCare Series B closing at ₹128 crore confirms that Infosys’s early-stage strategic bets are maturing into funded, globally validated platforms. July 23 earnings will be the next hard test of whether the FY27 guidance holds. 

Disclaimer

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.